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Abstract
Herbal medicines have been used to treat psoriasis for many years with anecdotal reports of efficacy which have attracted public attention. We seek to assess the effects 
of systemic herbal medicine in the treatment of psoriasis. Medical database PubMed/MEDLINE, AMED, CINAHL, and CENTRAL were searched. Randomised 
controlled trials of systemic herbal medicine used in the treatment of psoriasis included in the meta-analysis. Two reviewers independently applied eligibility criteria, 
assessed the quality of the trials and extracted data. Any discrepancies were discussed with additional reviewer to achieve consensus. Nine randomised controlled trials 
met the inclusion criteria. The trials randomised 785 participants. Three RCTs revealed that herbal medicine performed better than placebo control (RR=3.98, 1.36-
11.62, 95%CI, I2=68%, p=0.01), four RCTs demonstrated that the western drug competitor is superior to herbal medicine(RR=0.73, 0.53-0.97, 95%CI, I2=52%, 
p=0.03), two RCTs suggested that herbal medicine combined with other medication, (i.e. Auricular Acupuncture or Acitretin (a systemic retinoid), is more effective 
than herbal medicine alone (RR=1.92, 1.28-2.88, 95%CI, I2=0%, p=0.002). The results of one RCT indicated that herbal medicine reduced the occurrence of adverse 
reactions of Acitretin, when it was used in combination with herbal medicine. The ﬁndings are not conclusive due to the high risk of bias of the included trials and the 
limited number of trials testing individual herbal medicines. Further well-designed larger scale trials are required to determine the safety and efficacy of oral herbal 
interventions in the treatment of psoriasis.
Introduction
Psoriasis is a common, chronic, and recurrent inflammatory 
disease of the skin [1-3]. Worldwide psoriasis prevalence rates range 
from 0.6 percent to 4.8 percent [4]. Prevalence is higher in European 
1.5%-3.5% [5,6] compared with 0.1%-0.3% in the Far East and China 
[6,7]. Psoriasis impacts on daily living activities and may cause a 
financial burden on affected individuals [8-12]. A population-based 
survey conducted by Stern et al. [13] showed that 60% (n=4.5million) 
of patients report the disease affects their everyday life and 26% (n=4.5 
million) report a change or discontinuation of their daily activities. In 
the United States, total direct and indirect cost of psoriasis is estimated 
at 11.25 billion dollars annually, national direct medical costs increased 
from 650 million to 4.3 billion dollars over 6 years time period [8,11]. 
The cause of psoriasis is genetic with multiple inherited and acquired 
factors interacting [14].
Conventional treatment options focus on symptomatic 
management and may be associated with unwanted side effects and the 
development of drug tolerance [15-17]. Herbal medicine has been used 
as medicine for thousands of years [18], for example, saw palmetto was 
used for urinary symptoms in ancient Egypt [19], and a Chinese classic 
book named Inner Classic of the Yellow Emperor describes traditional 
Chinese herbs on skin diseases [20]. Herbal medicines are popular in 
America: in the 19th century, around two-thirds of medicine listed in 
the first edition of the United States Pharmacopoeia USP published 
in 1820 was botanical substances [21-23]. Fermentation products and 
highly purified or chemically modified botanical substances are not 
considered as botanical drug by FDA.
It is reported that in the China and USA around 43%-69% of patients 
inquire about traditional medicine (Herbal medicine, Traditional 
Chinese Medicine TCM, complementary alternative medicine CAM) 
to seek long-term psoriasis remission without side effects [24-29]. 
Studies have shown that some herbal medicines may be effective for 
psoriasis [30-33]. There were some alternative and complementary 
medicine CAM for psoriasis treatment reviews published previously 
[6,32,34-36], but literature reviews based on evidence from randomised 
control trials on systemic herbal intervention are rare. 
Due to lack of standard clinical practice on systemic herbal 
medication and a knowledge gap in regards of evidence-based 
medicinal use of systemic herbal medicine in psoriasis patients, the 
following two research questions were constructed:
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The primary aims: 
1. What, if any, evidence from randomized controlled trials 
(RCTs) exists for treatment of psoriasis with systemic herbal 
medicine?
2. What is the quality of the evidence for published systemic 
herbal medicine RCTs on psoriasis?
In order to answer these clinical questions, a systematic literature 
review was undertaken to evaluate the published RCTs on the safety 
and efficacy of treatment of psoriasis with systemic herbal medicine 
compared with placebo or comparator or herbal medicine +/- western 
medicine. The objectives of this review are to:
1. Identify and examine the safety and efficacy of herbal systemic 
intervention in the treatment of psoriasis
2. Critically appraise and summarise the available literature 
relating to systemic herbal therapy in psoriasis patients
3. Provide physicians and patients with up-to-date evidence-
based recommendations of systemic herbal medicine for 
psoriasis. 
The findings of the examined randomized controlled trials will be 
analysed.
Methods
We conducted a systematic review on the efficacy and safety of 
systemic herbal treatments for psoriasis.
Database and search strategies
The query search using patient characteristics, type of intervention, 
control, and outcome PICO format [35] was used to facilitate the 
literature searching process. MEDLINE/PubMed via PICO 
(http://pubmedhh.nlm.nih.gov/nlmd/pico/piconew.php)search 
provided by National Library of Medicine is applied as a primary 
search strategy in this paper. In PICO (patient, intervention, control, 
and outcome) category searching, “psoriasis” is used in patient 
category, keywords and synonyms “herbal medicine”, “Chinese 
medicine”,  “plant medicine”, “oriental medicine”, “kampo medicine”, 
“complementary medicine”, “alternative medicine” and “botanical 
drug” are used in intervention category, control and outcome category 
leave in blank. Publication type is selected as “clinical trial” and 
“review”. The relevant reference of review articles generated by PICO 
searching and reference of the references in the related literatures are 
also searched and retrieved. 
Electronic searches were conducted on the following databases: 
PubMed/MEDLINE, AMED (Allied and Complimentary Medicine), 
CINAHL, and Cochrane Central Register of Controlled Trials 
(CENTRAL). The search terms were a combination of Medical Subject 
Heading MeSh terms and their synonyms.A combination of MeSH 
terms and synonyms in PubMed/Medline, is listed in Table 1.
Inclusion/exclusion criteria
Inclusion criteria
•	 The research participants to be included in this review are 
patients who are clinically diagnosed with psoriasis or psoriatic 
arthritis.
•	 Placebo, no treatment or competitor medicine treatment as 
control interventions.
•	 No age limit was set.
•	 Only randomized controlled trials articles will be included in 
the analysis. 
•	 Intervention was any herbal medicine or combination of herbal 
medicines administered for systemic effect for psoriasis where 
herbal medicine(s) could be described as vegetable materials, 
which may include plant materials, algae, macroscopic fungi, 
combinations thereof, or may derived from plants or parts of 
plants i.e. leaves, stems, buds, flowers, roots or tubers.
•	 Limits were set for publication within 11 years (Jan 2002 to 
Jan 2013). The Consolidated Standards of Reporting Trials 
(CONSORT) Statement was first published in 1996 [39] as 
a clinical trial reporting guideline. The revised CONSORT 
Statement was published in 2001 and endorsed by three 
prestigious international medical journals, The Journal of the 
American Medical Association, Lancet and Annals of Internal 
Medicine. Therefore reviewers choose the clinical studies on 
psoriasis published since 2002.
Exclusion criteria
Articles excluded if:
•	 It is not published in the English language due to time 
constraints;
•	 It does not use  “randomization”;
•	 It does not have the primary end point as a clinical assessment;
•	 It contained interventions that used non-herbal therapies 
(vitamin, mineral supplements, fish oils, spa therapy, 
psychotherapy, acupuncture etc.);
•	 It used topical herbal therapies (ointment, cream, lotion etc.);
•	 It used therapies using plant-derived chemicals or synthetic 
chemicals that contain constituents of plants.
Analytic framework
Once the literature search was complete, two reviewers (T.Y.T and 
F.L) independently conducted the selection and data extraction. Any 
discrepancies were resolved by additional reviewer (J.D). 
No. Search term Search syntax Hits on 11 
July 2013
1 Randomized	controlled	trial Publication	type 435,264
2 Randomized	controlled	trial	as	topic MeSH 116,520
3 Psoriasis MeSH 34,292
4 Chinese	medicine MeSH 70,661
5 Herbal	medicine MeSH 21,078
6 Traditional	medicine MeSH 68,902
7 Phytotherapy MeSH 28,072
8 Botanical	drug MeSH 1,575
9 Oriental	medicine MeSH 16,104
10 Alternative	medicine MeSH 218,695
11 Complementary	medicine MeSH 192,255
12 Kampo	medicine MeSH 878
13 Term	1	or	2 435,264
14 Term	4	or	5	or	6	or	7	or	8	or	9	or	10	or	11	or	12 323,908
15 Term	3	and	13	and	14 	 42
Table 1. Literature	search	in	PubMed/Medline.
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From the list of included studies, the identified literature were 
appraised and assessed for methodological quality by using CONSORT 
Statement for Herbal Interventions [40] and for the risk of bias by 
using Cochrane Collaboration’s tool [41] for assessing risk of bias.
Data analysis
Data were analysed and the meta-analysis were conducted in 
statistical software RevMan5 that was provided by The Cochrane 
Collaboration IMS. Dichotomous data were presented as risk ratio RR 
Mantel-Haenszel method with a 95% confidence interval 95%CI. Meta-
analysis was performed if the intervention, control and outcome were 
all the similar. The statistical heterogeneity was presented as significant 
when I2 >50% or P<0.1.
Findings
Study selection
Literature search in PubMed/Medline (Table 1) yielded a total 
of 42 articles, in Cochrane/CENTRAL yielded a total of 49 articles, 
in CINAHLE/EBSCO host yielded a total of 124 articles, in AMED/
EBSCO host yielded a total of 75 articles respectively. PICO search via 
PubMed/Medline yield a total of 24 review articles. After screening the 
reference of review articles, total 8 clinical trials paper were identified. 
PICO search via PubMed/Medline yield a total of 25 clinical trials 
papers. After screening titles and abstracts, duplicates, non-herbal 
studies, non-English articles, non-controlled trials were excluded. A 
total 63 articles were screened out from electronic database searches. 
The selection of randomised controlled trials RCTs of herbal medicines 
for psoriasis is described in Figure 1, a flow diagram using the PRISMA 
template described in the PRISMA statement [42]. A total 13 full text 
articles were retrieved for further evaluation, 2 were not a randomised 
controlled trial, 1 was not a herbal intervention. Data were extracted 
from the remaining 10 [43-52], Hegazi et al. (2013) [52] study was 
excluded from the meta-analysis because it contains 4 intervention 
groups and therefore did not meet the inclusion criteria for this review.
Characteristics of included studies
The 9 studies from which data were extracted included a total of 
785 participants with psoriasis. The studies’ characteristics, methods, 
participants, interventions and outcome are summarized on Table 2. 
Clinical efficacy of herbal medicine
The 9 RCTs [43-51] involved 785 participants are conducted in 
meta-analysis by using the Cochrane Collaboration’s tool Review 
Manager (RevMan) [Computer program Version 5.2. Copenhagen: 
The Nordic Cochrane Centre, The Cochrane Collaboration, 2012]. 
These 9 RCTs were divided into 3 sub-groups according to the measures 
of intervention used: Group A: 3 RCTs [43,46,48] used herbal as 
intervention and were controlled using placebo as illustrated in Figure 
2. Group B: 4 RCTs [44-47] used herbal as intervention and were 
controlled using competitor (herbal or western drug) as illustrated in 
Figure 3. Group C: 2 RCTs [49,51] used herbal medicine in combination 
with other medicine as intervention and were controlled using herbal 
product alone as illustrated in Figure 4.
Three studies, Ahmadi et al. [43], Ho et al. [46], Lone et al. [48], 
included in the subgroup A meta-analysis (Figure 2) and listed in the 
first column “study or subgroup”. The individual study findings are 
displayed in this subgroup meta-analysis with binary outcomes (herbal 
intervention/placebo control). For example, in Figure 2, there are 9 out 
of 14 participants of herbal invention group show treatment efficacy, 
and there are 0 out of 14 participants of placebo control group show 
treatment efficacy in Ahmadi et al. [43] study. The influence of each 
individual study on overall meta-analysis are weighted at 11.5%, 73.3% 
and 15.1% by Ahmadi et al. [43], Ho et al. [46] and Lone et al. [48] 
respectively. The Risk Ratio (RR) effect measure, Mantel-Haenszel (M-
H) statistical method and the Fixed Effect analysis model with 95% 
Confidence Interval used to perform the meta-analysis. Each study 
is represented by a horizontal line on the forest plot. There is a blue 
square box in the line for each study. The width of the line shows the 
confidence intervals of the effect estimate of individual studies. The 
mid-point of the box represents the point effect estimate, that is, the 
mean effect estimate for each study. The area of the box represents 
the weight given to the study. The black diamond shape below the 3 
studies represents the overall effect. The width of the diamond shows 
the confidence intervals for the overall effect estimate. The middle of 
the diamond sits on the value for the overall effect estimate of the Risk 
Ratio (RR). There is a vertical line that corresponds to the value 1 in 
the forest plot. This is the line of no treatment effect. Note also that 
it says “Favours Placebo” to the left of the vertical line and “Favours 
Herbal” to the right of the vertical line. On the forest plot shown on 
Figure 2, the 95% confidence intervals of the two studies (Ho et al. [46], 
 
Figure 1.	Flow	chart	of	selection	of	randomised	controlled	trials	(RCTs)	of	systemic	herbal	
medicines	for	psoriasis.
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Ahmadi et al. 2008
Methods Design:	randomised,	double-blind,	placebo-controlled
Duration:	6	months	trial	and	6	months	follow-up
Interval	of	assessment:	every	4	weeks
Participants Number	randomised:	28	(14	in	each	group)
Sex	(M/F):	5/9	in	treatment	group	and	6/8	in	placebo	groups
Age	of	participants:	Not	specified
Country	and	setting:	Iran,	single	university	centre
Inclusion	criteria	of	the	study
•	Diagnostic	criteria:	clinical	diagnosis	of	psoriasis	vulgaris
Exclusion	criteria	of	the	study
•	Erythrodermic
•	Exfoliative
•	Pustular	psoriasis
•	Skin	infections,
•	Systemic	and/or	topical	antipsoriatic	treatment	in	the	8-week	prior	to	the	study,
•	PUVA,	UVB
•	pregnancy	or	breastfeeding
Interventions •	Treatment	group:	HESA-A	tablet	25	mg/Kg	BD	orally
•	Placebo	group:	Not	specified
Outcomes 6-point	scale:	absent	(no	evidence	of	psoriasis),	very	mild	(controlled,	but	not	entirely	cleared),	mild	(lesions	of	slight	redness,	thickness	and	scaliness),	moderate	
(red	lesions	with	moderate	thickness	and	scaliness),	severe	(very	red	lesions	with	severe	thickness	and	scaliness),	and	very	severe	(extremely	red	lesions	with	very	
severe	thickness	and	scaliness).
Notes
Chang et al. 2006
Methods Design:	randomised,	active	comparator-controlled
Duration:	8	weeks
Interval	of	assessment:	start	and	end	of	study
Participants Number	randomised:	120	(60	in	each	group)
Sex	(M/F):	34/26	in	treatment	group	and	31/29	in	placebo	group
Age	of	participants	(mean):	35.47	±	12.5	in	treatment	group	and	36.40	±	11.32	in	placebo	group
Country	and	setting:	China,	single	centre
Inclusion	criteria	of	the	study
•	Diagnostic	criteria:	Principle	for	Directing	Clinical	Studies	on	New	Drugs	of	Chinese	Materia	Medica	for	Treating	Psoriasis,	MOH,	China
•	Blood-heat	syndrome	in	traditional	Chinese	medicine
Exclusion	criteria	of	the	study
•	Severe	cardiovascular
•	Cerebrovascular
•	Pustular	psoriasis
•	Hepatic	diseases
•	Renal	diseases
•	Mental	disorders
•	Women	in	pregnancy	or	breastfeeding
Interventions •	Treatment	group:	Yin	Xie	Ping	Granules,	4.5	g	each	time,	2	times	daily
•	Control	group:	Xiao	Yin	Pian	Tablets,	7	tablet	each	time,	3	times	daily
Outcomes 1.	Degree	of	silvery	scales
2.	Red	patches
3.	Pruritus
4.	Area	of	papules
Notes Ingredients	used	in	control	group	Xiao	Yin	Pian	Tablets	was	not	stated
Deng et al. 2010
Methods Design:	randomised,	active	comparator-controlled
Duration:	4	weeks	and	3	months	follow-up
Interval	of	assessment:	at	4	weeks,	3	months.
Participants Number	randomised:	64	(32	in	each	group)
Sex	(M/F):	19/13	in	treatment	group	and	22/10	in	placebo	group
Age	of	participants	(mean,	rang):	48.7	(28-62)	in	treatment	group	and	45.6	(24-68)	in	placebo	group
Country	and	setting:	China,	single	centre
Inclusion	criteria	of	the	study
•	Diagnostic	criteria:	clinical	diagnosis	of	psoriasis	vulgaris
•	Blood-heat	syndrome	in	traditional	Chinese	medicine
Exclusion	criteria	of	the	study
•	Severe	cardiovascular
•	Cerebrovascular
•	Prior	Acitretin	treatment	within	1	months
•	Hepatic	diseases
•	Renal	diseases
•	Mental	disorders
•	Women	in	pregnancy	or	breastfeeding
Interventions •	Treatment	group:	Xuebijing	injection,	30	ml	daily
•	Control	group:	Acitretin	Tablets,	30	mg/d
Outcomes PASI	score
Table 2. Characteristics	of	included	studies.
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Notes Ingredients	used	in	control	group	Xiao	Yin	Pian	Tablets	was	not	stated.
Concomittent	treatment:	permitted	emollients.
Ho et al. 2009
Methods Design:	randomised,	placebo-controlled
Duration:	6	months
Interval	of	assessment:	every	2	months
Number	randomised:	61
	
Participants
Sex	(M/F):	26/22	total	(18/2	in	MTX	group,	14/7	in	TCM	group,	18/2	in	placebo	group)
Age	of	participants	(mean,	range):	38.45	(21-68)	in	MTX,	43.45	(25-80)	in	TCM,	43.45	(27-61)	in	placebo
Country	and	setting:	China,	single	centre
Inclusion	criteria	of	the	study
•	Diagnostic	criteria:	not	state
•	Psoriatic	plaque	affect	more	than	20%	of	body	surface	area
•	aged	more	than	18-year-old
•	Written	informed	consent
Exclusion	criteria	of	the	study
•	Renal	or	liver	impairment
•	Active	infection
•	Immunosuppression	or	other	serious	concomitant
•	Women	in	pregnancy	or	breastfeeding
•	MTX	group:	Methotrexate	(2.5	mg/week	to	30	mg/week),	Folic	acid	5	mg	daily
Interventions •	TCM	group:	Wen-tong-hua-yu	capsule,	dose	not	stated
•	Placebo	group:	ingredients	and	dose	not	stated
Outcomes 1.	PASI	score
2.	PGA	and	PDI
Li et al. 2008
Methods Design:	randomised,	active	comparator-controlled
Duration:	4	weeks
Interval	of	assessment:	every	2	weeks
Participants Number	randomised:	58
Sex	(M/F):	37/21	total	(19/11	in	TCM	group,	18/10	in	placebo	group)
Age	of	participants	(mean,	range):	42.16	±	11.26	in	TCM,	38.08	±	9.64	in	placebo
Country	and	setting:	China,	single	centre
Inclusion	criteria	of	the	study
•	Diagnostic	criteria:	Practice	guidelines	for	diagnosis	and	therapeutic	effect	evaluation	of	disease.	Peoples's	Military	Medical	Press.	1998.	Beijing.	China
•	Blood-heat	syndrome	in	Traditional	Chinese	Medicine.	Diagnostic	and	therapeutic	effect	evaluation	criteria	for	diseases	and	syndromes	of	traditional	Chinese	
medicine.
Nanjing	University	Press.	1994.	China
•	Aged	from	18	to	60	years	old
•	Psoriasis	history	from	3	months	to	20	years
Exclusion	criteria	of	the	study
•	Unknown	high	fever	in	previous	two	months
•	Prior	systemic	immunosuppressants	therapy	used	within	three	months
•	Prior	high	potent	corticosteroid	application	within	three	months
•	Psoriatic	type	rather	than	Psoriasis	vulgaris
•	Women	in	pregnancy	or	breastfeeding
Interventions •	Treatment	group:	Qinzhu	Liangxue	Decoction,	30	ml	two	times	daily.
•	Controlled	group:	Compound	Amino-polypeptide	Tablets,	5	tables,	three	times	daily.
Outcomes 1.	PASI	score	(Psoriasis	Area	and	Severity	Index)
2.	DLQI	score	(Dermatology	Life	Quality	Index)
3.	VEGF	level	(Vascular	Endothelial	Growth	Factor)
Notes
Lone et al. 2011
Methods Design:	randomised,	single-blind,	placebo-controlled	study
Duration:	8	weeks
Interval	of	assessment:	fortnightly
Participants Number	randomised:	30
Sex	(M/F):	21/9	total	(20	in	herbal	group,	10	in	placebo	group)
Age	of	participants	11-60	years
Country	and	setting:	India,	Bangalore,	single	centre
Inclusion	criteria	of	the	study
•	Illness	history
•	Dermatological	examination
•	Aged	from	11	to	60	years	old
•	Biopsy	of	the	affected	area
Exclusion	criteria	of	the	study
•	Aged	blow	11	years	and	above	60	years
•	Prior	systemic	immunosuppressants	therapy	used	within	three	months
•	Unable	to	give	consent
•	Psoriasis	concomitant	with	diabetes,	vitiligo,	dermatophytosis,	pityriasis,	eczema
•	Women	in	pregnancy	or	breastfeeding	or	mentally	retarded	persons
•	Priorlocal	or	systemic	antipsoriatic	therapy	used	within	two	months
Tang TY (2015) Current evidence on the effectiveness of systemic herbal medicine for psoriasis: A systematic review with meta-analysis
Glob Dermatol, 2015             doi: 10.15761/GOD.1000136  Volume 2(3): 117-127
Interventions •	Treatment	group:	Majoon	Ushba	5	g	two	times	daily,	Rogbane	Hindi	5-10	ml	topical	apply	two	times	daily.
•	Controlled	group:	Wheat	flour	5	g	two	times	daily,	Coconut	oil	topical	apply	two	times	daily.
Outcomes 1.	Itching	severity,	scaling	severity,	erythema	severity.
2.	PASI	score	(Psoriasis	Area	and	Severity	Index)
Notes
Lu et al. 2012
Methods Design:	randomised,	active	comparator-controlled
Duration:	8	weeks
Interval	of	assessment:	every	2	weeks
Participants Number	randomised:	84
Sex	(M/F):	61/23	total	(28/15	in	TCM	+	Auricular	therapy	group,	33/8	in	TCM	group)
Age	of	participants	(mean,	range):	38.58	±	13.13	in	TCM	+	Auricular,	38.98	±	13.80	in	TCM
Country	and	setting:	China,	single	centre
Inclusion	criteria	of	the	study
•	Diagnostic	criteria:	Clinical	guidelines	of	Psoriasis	2008	by	Chinese	Medical	Association	China
•	Aged	from	18	to	65	years	old
•	Sign	informed	consent.
Exclusion	criteria	of	the	study
•	Allergic	to	Yinxieling	Formula	or	the	composition	of	it
•	Women	in	pregnancy	or	breastfeeding
•	Prior	oral	steroid	therapy	used	within	two	weeks
•	Prior	oral	retinoid	or	topical	steroid	treatment	within	one	week
•	Arhropathic,	pustular,	or	erythrodermic	psoriasis
•	Severe	heart,	cerebrovascular,	live,	kidney,	hematopoietic	system,	cancer,	psychosis	diseases.
Interventions •	Treatment	group:	Auricular	+	Yinxieling	Decoction,	10	ml	two	times	daily.
•	Controlled	group:	Yinxieling	Decoction,	10	ml	two	times	daily.
Outcomes 1.	PASI	score	(Psoriasis	Area	and	Severity	Index)
2.	DLQI	score	(Dermatology	Life	Quality	Index)
3.	VAS	(Visual	Analogue	Scale)
4.	SDS	(Self-rating	Depression	Scale)
5.	SAS	(Self-rating	Anxiety	Scale)
Notes
Yang et al. 2002
Methods Design:	randomised,	active	comparator-controlled
Duration:	8	weeks
Interval	of	assessment:	before	and	end	of	study
Participants Number	randomised:	260
Sex	(M/F):	144/116	total	(88/72	in	treatment	group,	56/44	in	comparator	controlled	group)
Age	of	participants	(mean,	range):	30.0	±	2.8	in	treatment	group,	30.0	±	20	in	TCM
Country	and	setting:	China,	single	centre
Inclusion	criteria	of	the	study
•	Not	stated
Exclusion	criteria	of	the	study
•	Not	stated
•	Treatment	group:	LeYin	Decoction,	50ml	two	times	daily,	and	Vitamin	E	moisturizer	application.
Interventions •	Controlled	group:	Yinxieling	Granule,	10	g	two	times	daily	and	Vitamin	E	moisturizer	application.
Outcomes 1.	Therapeutic	effect	evaluation
2.	Changes	of	T-cell	subsets
3.	Adverse	reactions
Notes
Zhang et al. 2009
Methods Design:	randomised,	active	comparator-controlled
Duration:	8	weeks
Interval	of	assessment:	before	and	at	end	of	week	8
Participants Number	randomised:	80
Sex	(M/F):	74/6	total	(37/2	in	TCM+Acitretin,	37/4	in	TCM	group)
Age	of	participants	(mean,	range):	42.6	in	TCM	+	Auricular,	43.1	in	TCM
Country	and	setting:	China,	single	centre
Inclusion	criteria	of	the	study
•	Blood-heat	syndrome	in	Traditional	Chinese	Medicine	Duiding	Principles	of	Clinical
Research	on	New	Drugs	of	Traditional	Chinese	Medicine.	China
•	Diagonosed	with	psorasis
Exclusion	criteria	of	the	study
•	Severe	photosensitivity
•	Women	in	pregnancy	or	breastfeeding	or	planing	for	pregnancy
•	Sensitive	to	acitretin
•	Prior	oral	acitretin	or	immunosuppressive	therapy	within	two	months
•	Complicated	with	other	skin	diseases
•	Severe	heart,	cerebrovascular,	live,	kidney,	hematopoietic	system,	cancer,	psychosis	diseases.
Interventions •	Treatment	group:	TCM	decoction	+	Qingkailing	Injection	40ml	daily	+	Acitretin	20-30	mg	daily
•	Controlled	group:	TCM	decoction	+	Qingkailing	Injection	40	ml	daily
Outcomes 1.	PASI	score	(Psoriasis	Area	and	Severity	Index)
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Lone et al. [48]) overlap 1, the 95% confidence intervals of the study 
(Ahmadi et al. [43]) do not overlap 1. There is statistical significance at 
the meta-analysis level. The herbal intervention is better than control 
as the overall effect estimate and its 95% confidence intervals are to the 
right of the line of no treatment effect. The total number of participants 
in the herbal intervention groups is 48 and the control group is 41.
The heterogeneity test is shown at the bottom of the Figure 
2 on the left hand side, the number of interest is the I2 value. I2 was 
developed and introduced as the preferable and more reliable test for 
heterogeneity (Higgins et al. [52]). I2 ranges between 0 and 100%, the 
values of I2 equal to 25%, 50%, and 75% representing low, moderate, 
and high heterogeneity, respectively. Heterogeneity measures the 
variability between studies, in other words it gives an indication how 
comparable studies in the meta-analysis are. A useful visual guide to 
assess heterogeneity is to check the overlap of the CIs, i.e. the horizontal 
lines in the meta-analysis graph. Studies are regarded as homogeneous 
if CIs of all studies overlap. The heterogeneity of this subgroup studies 
are moderate (I2=68).The test for overall effect is statistical significance 
with the probability value (p=0.01).
Four studies, Chang et al. [44], Deng et al. [45], Ho et al. [46] Li et 
al. [47], included in the subgroup B meta-analysis (Figure 3). The total 
number of participants in the herbal intervention groups is 136 and the 
competitor group is 139. The mean effect estimate for 3 studies Deng 
et al. [45], Ho et al. [46], Li et al. [47] which using herbal intervention 
compare with western drug treatment favours western drug treatment. 
The 95% confidence intervals of Ho et al. [46] study are to the left of 
the line of no treatment effect that show the MTX is superior than the 
herbal intervention. Chang et al. [44] used competitive herbal medicine 
to compare with investigative herbal medicine, the mean effect 
estimate favours herbal intervention, but the 95% confidence intervals 
overlap 1. On the forest plot shown on Figure 3, the competitor is 
better than herbal intervention as the overall effect estimate and its 95% 
confidence intervals are to the left of the line of no treatment effect. 
The heterogeneity of this subgroup studies are moderate (I2=52). The 
test for overall effect is statistical significance with the probability value 
(p=0.03).There is statistical significance at the meta-analysis level.
Two studies, Lu et al. [49] and Zhang et al. [51] included in the 
subgroup C meta-analysis (Figure 4). The total number of participants 
in the herbal intervention groups is 82 and the herbal combine other 
medication group is 81. The mean effect estimates for these two studies 
favours herbal medicine in combination with Auricular acupuncture 
or western medicine Acitretin group. The 95% confidence intervals of 
Lu et al. [49] study are to the right of the line of no treatment effect 
that show the herbal combing with Auricular therapy is superior than 
the herbal intervention alone. Zhang et al. [51] used herbal medicine 
combine with Acitretin to compare with herbal medicine alone, the 
mean effect estimate favours herbal combination therapy, but the 95% 
confidence intervals overlap 1. On the forest plot shown on Figure 4, 
the competitor is better than herbal intervention as the overall effect 
estimate and its 95% confidence intervals are to the right of the line 
of no treatment effect. The heterogeneity of this subgroup studies are 
 
Figure 2.	Subgroup	A.	Meta-analysis	of	Effective	Rate	of	Herbal	vs.	Placebo	(CI: confidence	interval,	M-H:	Mantel-Haenszel).
 
Figure 3.		Subgroup	B.	Meta-analysis	of	Effective	Rate	of	Herbal	vs.	Competitor	(herbal	or	western	drug)	(CI: confidence	interval,	M-H:	Mantel-Haenszel).
Figure 4.	Subgroup	C.		Meta-analysis	of	Effective	Rate	of	Herbal	+	other	medication	vs.	Herbal	Alone		(CI: confidence	interval,	M-H:	Mantel-Haenszel).
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low (I2=0). The test for overall effect is statistical significance with the 
probability value (p=0.002). There is statistical significance at the meta-
analysis level.
Synthesis and interpretation
In total, 9 RCTs [43-52] were included in the qualitative synthesis 
(Table 2) and 9 RCTs [43-52] were included in the meta-analysis 
(Figures 2-4). Regarding the effectiveness of herbal medication for 
psoriasis, 3 RCTs revealed that herbal medicine performed better than 
placebo control, 3 RCTs showed that the western drug competitor is 
superior than herbal intervention, 1 RCT showed the herbal medicine 
performed better than competitive herbal medicine, 2 RCTs suggested 
that herbal combined with other medication (Auricular or Acitretin) 
is better than herbal medicine alone. Regarding adverse reactions, the 
abnormal liver function were reported in 8 participants in Acitretin 
(western drug) group (Deng et al.) [45], the results of Zhang et al. 
[51] indicated that herbal medicine reduce the occurrence of adverse 
reaction of western medicine Acitretin when it is used combine with 
herbal medicine. The adverse events were reported by 65% in the MTX 
(western drug) group, 48% in the herbal intervention group and 30% in 
the placebo group (Ho et al.) [46].
This review showed no significant safety concerns regarding 
systemic herbal medication for psoriasis. But in these 9 studies, herbal 
medicine was only administered for 4 weeks to 6 months under 
controlled conditions. The included studies used different methods 
of medication delivery:  4 studies [47,49-51] used decoctions,1 used 
powder (Lone et al.[48]), 1 used tablet (Ahmadi et al. [43]), 2 used 
capsule (Hagazi et al. [52], Ho et al. [46]), 1 used granules (Chang et al. 
[44]) and 1 used injection (Deng et al. [45]). It remains unclear if the 
different methods of herbal medicine delivery influence their treatment 
effects [53,54].
Quality evaluation on the evidence
The risk of bias assessment is conducted by using the Cochrane 
Collaboration’s tool for assessing risk of bias [41]. The overall risk 
of assessment found that the quality of studies was poor (Figure 5), 
therefore the results from the meta-analysis have to be translated with 
caution. None of 9 RCTs was judged with “Low Risk” in all domains for 
bias assessment. All 9studies had “High Risk” or “Unclear” judgements 
in ≥2 domains (Figure 5). 
7 RCTs (Ahmadi et al. [43], Chang et al. [44], Ho et al. [46], Li et 
al. [47], Lone et al. [48], Yang et al. [50], Zhang et al. [51]) did not state 
the method used to conceal the allocation sequence, hence selection 
bias may occurred due to inadequate concealment of allocations prior 
to assignment. 
6 RCTs (Chang et al. [44], Deng et al. [45], Ho et al. [46], Li et 
al. [47], Yang et al. [50], Zhang et al. [51]) failed to blind study 
participants and personnel from knowledge of which intervention a 
participant received. The granules were used as intervention and tablets 
were used as control (Chang et al. [44]). The herbal injection was used 
as intervention and tablets used as control (Deng et al. [45]). Capsules 
were used as intervention, tablets were used as competitor, placebos 
were used as control, but investigators did notdescribe the details on 
the chemical properties of the herbal placebo (Ho et al. [46]). The 
decoctions were used as intervention and tablet were used as control 
(Li et al. [47]). The decoctions were used as intervention and granule 
were used as control (Yang et al. [50]). The decoction combined with 
injection and tablet used as intervention and decoction plus injection 
used as control (Zhang et al. [51]). Therefore the performance bias may 
incur due to knowledge of the allocated interventions by participants 
and personnel during these studies. 
The detection bias is high risk in all 9 RCTs because none of these 
studies describe measures used to blind outcome assessors from 
knowledge of which intervention a participant received and provide 
any information relating to whether the intended blinding was effective.
The quality of reporting is evaluated by using the CONSORT 
framework [40] to check if the adequate important aspects of research 
information are included in reports of controlled clinical trials of 
Figure 5.	Summary	of	risk	of	bias	assessment.
(+:	Low	Risk,	-:	High	Risk,	?:Unclear)
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If CONSORT items for RCT's of herbal medicine interventions reported on the literature?
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Figure 6.	Summary	of	CONSORT	22	items	for	RCTs	of	herbal	medicine.
herbal interventions. The 22-item checklist of the CONSORT for 
herbal intervention is compiled on Figure 6. 
None of 9 RCTs report the item 4D (Qualitative Testing) (Figure 
6) investigational product’s chemical fingerprint and methods used 
and which laboratory performed them. Herbal medicines are often 
contaminated [55], thus a complete description of any special testing 
or purity testing (e.g. heavy metal test) and the removal of unwanted 
components should be included in reports. 
Only two RTCs (Ahmadi et al. [43], Lone et al. [48]) reported 
blinding item 11 (Blinding) (Figure 6). Ahmadi et al. [43] state the 
trials as “double-blind”, but did not give the details on the properties of 
the herbal placebo. Lone et al. [48] state the trails as “single blind” and 
specified wheat flour serviced as control to compare with investigational 
herbal “Majoon Ushba”. However these 2 RCTs did not state whether 
those investigators administering the intervention and those assessing 
the outcomes were blinded, how the success of blinding of participant 
was evaluated.
None of 9 RCTs report the external validity of trial result item 12 
(Generalizability) (Figure 6). Generalizability is the extent to which 
the results of a study hold true in other individuals or groups, other 
similar interventions, dosages, timing, administration routes and other 
settings [40]. The herbal medicinal products are available widely on the 
market with variable quality and ingredients, how the products used in 
the RCTs relate to what is available and used by consumers and health 
care practitioners is quite valuable information which enable reader to 
understand products that may act similarly to the one used in the trial.
The 9 included RCTs reported adequate information on Title 
and Abstract section (item 1) and Introduction section (item 2), 
showed the minor issue on reporting Result section (item 13-19) and 
Discussion section (item 20-22) as item 13 (Participant Flow) and item 
21 (Generalizability) are uncompleted reported, and showed the non-
adequate reporting in Methods section (item 3-12) because the item 4D 
(Qualitative Testing), item 8 (Sequence Allocation), item 9 (Allocation 
Concealment), item 10 (Implementation) and item 11 (Blinding) are 
poorly reported lacked with details. Such findings on checklist of the 
CONSORT for herbal intervention (Figure 6) are also corresponded 
with the risk of bias assessment (Figure 5).
Discussion
This review did not include unpublished studies, case reports, case-
series, or retrospective studies, non-English studies. The reviewers 
are aware of the high possibility of publication bias due to exclusion 
of non-English language publication in this review. The exclusion of 
Chinese language articles may result in partial estimate of intervention 
effect for herbal interventions [56].
Only 9 small inadequate reported RCTs with short study duration 
were available for assessment. None was effectively blinded. Although 
blinding presents practical difficulties when herbal decoctions are used, 
without blinding it is impossible to conclude that the benefit observed 
was due to herbal medicine alone. The evidence is inconclusive due to 
the high risk of bias of the included trials and the limited number of 
trials with each of herbal medication formulas, as well as the limited 
number of included participants and patient relevant outcomes. Hence 
the author cannot be certain of the effectiveness and safety of the 
studies in this review of herbal medicines for the treatment of psoriasis.
To obtain a high level of evidence on herbal medicines on 
psoriasis treatment and to give guidance on clinical practice, more 
international, multicentre, rigorously designed, high-quality trials with 
large sample sizes are required. Attention should be paid to the sample 
size estimation, the definition of outcomes, duration of treatment 
and follow-up, and the reporting of adverse events. In addition, the 
following methodological issues should be addressed: the trial design 
should be according to the SPIRIT Statement (www.spirit-statement.
org), including the methods of randomisation and blinding with the 
use of placebo with the same appearance, taste, and smell, and reporting 
trials according to the CONSORT statement for herbal intervention 
(www.consort-statement.org). To improve the quality of future trials, 
the author suggest that all researchers receive the necessary training on 
clinical trial methodology before designing a trial and register the trial 
on an internationally recognised public trial registry. From the results 
of this review, the detailed description of the pharmacology of the 
interventions and clinical outcomes should be emphasised for herbal 
medicines. Information about species, geographical origin of herbs, 
season for collecting the herbs, and quality of the preparations should 
be provided [40].
3 RCTs (Figure 2) revealed that herbal medicine performed 
better than placebo control (RR=3.98, 1.36-11.62, 95%CI, I2=68%, 
p=0.01), but results were heterogeneous (I2 >50%). 4 RCTs (Figure 
3) showed that the western drug competitor is superior than herbal 
intervention (RR=0.73, 0.53-0.97, 95%CI, I2=52%, p=0.03), but results 
were heterogeneous (I2 >50%). 2 RCTs (Figure 4) suggested that herbal 
medicine combined with other medication (Auricular or Acitretin) is 
more effective than herbal medicine alone (RR=1.92, 1.28-2.88, 95%CI, 
I2=0%, p=0.002), but these results need to be interpreted with caution 
due to methodological weaknesses and the lack of replicated studies. 
The results of 1 RCT (Zhang et al. [51]) indicated that herbal medicine 
reduce the occurrence of adverse reaction of western medicine Acitretin 
when it is used combine with herbal medicine. We found no signiﬁcant 
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difference on adverse effects between herbal medicine and placebo 
control groups. However, the ﬁndings are not conclusive due to the 
high risk of bias of the included trials and the limited number of trials 
testing individual herbal medicines. All the studies had small sample 
size that can decrease the chances of finding a positive effect if one truly 
exists, moreover most of the studies had short study duration from 4 
weeks to 8 weeks which can hide potential undetectable long-term side 
effect of investigational herbal medicine if one truly exists. In reviewers’ 
opinion, it is premature to recommend any of these herbal medicines 
to psoriasis patients. Therefore there is clearly a need for well-designed 
and larger scalerigorous randomized controlled trials with CONSORT 
reporting format to determine the safety and efficacy of these herbal 
interventions.
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